Meta Information

ID:nmn-liposomal

Name:Liposomal NMN

Schema Version:1.5

Alternate Names

• Liposomal Nicotinamide Mononucleotide

Active Compound

nicotinamide_mononucleotide

Intervention Type

therapeutic_agent

Delivery

Route:

oral

Scope:

• systemic

Regulatory Status

• us:dietary_supplement

Indication

Focus:

healthspan

Description:

Aims to boost systemic NAD+ levels to support cellular energy, metabolism, and DNA repair, potentially mitigating aspects of age-related decline.

Typical Protocol

• Typical daily doses range from 100mg to 500mg, taken orally, often in the morning.
• The liposomal formulation is intended to increase bioavailability, often allowing for lower doses than standard NMN.
• Some protocols suggest co-administration with a sirtuin activator like resveratrol or pterostilbene.

Expected Cost Mean

Low Cost:

50

High Cost:

120

Cost Type:

monthly

Description:

Premium cost over standard NMN due to the encapsulation process; not covered by insurance.

Summary

Nicotinamide Mononucleotide (NMN) is a direct precursor to NAD+, a critical coenzyme for cellular energy production (ATP) and DNA repair that declines significantly with age. Liposomal encapsulation is a delivery technology that encases NMN in a lipid sphere to protect it from degradation in the digestive system, aiming to significantly increase its absorption and bioavailability compared to standard NMN powder.

Purpose

Boosts cellular NAD+ levels to support energy and repair.

Card Summary

A high-bioavailability form of the NAD+ precursor NMN, designed to support cellular energy, metabolism, and DNA repair pathways that decline with age.

Drug Class

Drugs In Class

Empty Array

Impact

Score:

4.5

Justification:

Targets a key aging pathway (NAD+ decline), but human healthspan benefits remain unproven.

Evidence

Grade:

B

Score:

5.5

Justification:

Small human trials show biomarker and physiological improvements, but long-term healthspan data is lacking.

Safety

Score:

3

Justification:

Generally well-tolerated in short-term human studies; long-term safety data is unavailable.

Flags

• Liposomal delivery may significantly alter pharmacokinetics and required dosage compared to standard NMN.
• In late 2022, the US FDA ruled that NMN cannot be marketed as a dietary supplement, though it remains widely available.
• Long-term effects and safety in humans are not yet established.
• Quality and dosage can vary significantly between manufacturers; third-party testing is recommended.

Verdict

A promising but unproven method to boost NAD+ with enhanced bioavailability.

Created

2026-06-12T17:47:24.879818Z

Ai Model

Gemini 2.5 Pro (High)